William Brian Dalton (W Brian Dalton, William B Dalton)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Leukemia & lymphoma

Expert review of hematology

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

In Young Choi, Jonathan P Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou, Riley E Bergman, Céline Philippe, James L Manley, Kevin Rouault-Pierre, Bing Li, Daniel Howard Wiseman, Kiran Batta, Madhu M Ouseph, Elsa Bernard, Benjamin Dubner, Xiao Li, Torsten Haferlach, Anna Koget, Salman Fazal, Tania Jain, Christopher D Gocke, Amy E DeZern, William Brian Dalton
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Blood advances (2024)
In Young Choi, Jonathan P Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou, Riley E Bergman, Céline Philippe, James L Manley, Kevin Rouault-Pierre, Bing Li, Daniel H Wiseman, Kiran Batta, Madhu Ouseph, Elsa Bernard, Benjamin Dubner, Xiao Li, Torsten Haferlach, Anna Koget, Salman Fazal, Tania Jain, Christopher D Gocke, Amy E DeZern, William Brian Dalton
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Blood advances 8 (15) (2024)
In Young Choi, Jonathan P Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou, Riley E Bergman, Céline Philippe, James L Manley, Kevin Rouault-Pierre, Bing Li, Daniel H Wiseman, Kiran Batta, Madhu Ouseph, Elsa Bernard, Benjamin Dubner, Xiao Li, Torsten Haferlach, Anna Koget, Salman Fazal, Tania Jain, Christopher D Gocke, Amy E DeZern, William Brian Dalton
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Blood advances 8 (15) (2024)
In Young Choi, Jonathan P Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou, Riley E Bergman, Céline Philippe, James L Manley, Kevin Rouault-Pierre, Bing Li, Daniel H Wiseman, Kiran Batta, Madhu Ouseph, Elsa Bernard, Benjamin Dubner, Xiao Li, Torsten Haferlach, Anna Koget, Salman Fazal, Tania Jain, Christopher D Gocke, Amy E DeZern, William Brian Dalton
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Blood advances 8 (15) (2024)
In Young Choi, Jonathan P Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou, Riley E Bergman, Céline Philippe, James L Manley, Kevin Rouault-Pierre, Bing Li, Daniel Howard Wiseman, Kiran Batta, Madhu M Ouseph, Elsa Bernard, Benjamin Dubner, Xiao Li, Torsten Haferlach, Anna Koget, Salman Fazal, Tania Jain, Christopher D Gocke, Amy E DeZern, William Brian Dalton
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Blood advances (2024)
In Young Choi, Jonathan P Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou, Riley E Bergman, Céline Philippe, James L Manley, Kevin Rouault-Pierre, Bing Li, Daniel H Wiseman, Kiran Batta, Madhu Ouseph, Elsa Bernard, Benjamin Dubner, Xiao Li, Torsten Haferlach, Anna Koget, Salman Fazal, Tania Jain, Christopher D Gocke, Amy E DeZern, William Brian Dalton
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Blood advances 8 (15) (2024)
In Young Choi, Jonathan P Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Panagiotis Tsakiroglou, Riley E Bergman, Céline Philippe, James L Manley, Kevin Rouault-Pierre, Bing Li, Daniel H Wiseman, Kiran Batta, Madhu Ouseph, Elsa Bernard, Benjamin Dubner, Xiao Li, Torsten Haferlach, Anna Koget, Salman Fazal, Tania Jain, Christopher D Gocke, Amy E DeZern, William Brian Dalton
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts. Blood advances 8 (15) (2024)
Khaled Sanber, Kevin Ye, Hua-Ling Tsai, Matthew Newman, Jonathan A Webster, Ivana Gojo, Gabriel Ghiaur, Gabrielle T Prince, Lukasz P Gondek, B Douglas Smith, Mark J Levis, Amy E DeZern, Alexander J Ambinder, William Brian Dalton, Tania Jain
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leukemia & lymphoma (2023)
Amy E DeZern, William Brian Dalton
How low risk are low risk myelodysplastic syndromes? Expert review of hematology 15 (1) (2022)
Theodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, Amy E DeZern, Gabriel Ghiaur, William Brian Dalton, Ivana Gojo, Gabrielle T Prince, Jonathan A Webster, Alexander Ambinder, B Douglas Smith, Mark J Levis, Ravi Varadhan, Richard J Jones, Tania Jain
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leukemia & lymphoma 63 (8) (2022)
Theodoros Karantanos, Patric Teodorescu, Brandy Perkins, Ilias Christodoulou, Christopher Esteb, Ravi Varadhan, Eric Helmenstine, Trivikram Rajkhowa, Bogdan C Paun, Challice L Bonifant, William Brian Dalton, Lukasz P Gondek, Alison R Moliterno, Mark J Levis, Gabriel Ghiaur, Richard J Jones
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Science advances 8 (7) (2022)
William Brian Dalton
The metabolic reprogramming and vulnerability of SF3B1 mutations. Molecular & cellular oncology 7 (3) (2020)